The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas

被引:36
作者
Sugo, H [1 ]
Takamori, S [1 ]
Kojima, K [1 ]
Beppu, T [1 ]
Futagawa, S [1 ]
机构
[1] Juntendo Univ, Sch Med, Dept Surg 2, Bunkyo Ku, Tokyo 1130033, Japan
来源
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1999年 / 29卷 / 09期
关键词
hepatocellular carcinoma; p53; mutation; postoperative recurrence;
D O I
10.1007/BF02482774
中图分类号
R61 [外科手术学];
学科分类号
摘要
The significance of p53 mutations in the primary lesion for recurrent hepatocellular carcinoma (HCC) was evaluated. Mutations of p53 were examined using nonradioisotopic (nonRI)-polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) in 98 resected HCCs. Of the 98 cases, 25 (26%) had a p53 mutation. In 83 patients who survived surgery, the presence of a p53 mutation was associated with a shortened overall survival (P < 0.001) and a shortened cancer-free survival (P < 0.05). In 43 patients who developed recurrence, there was no statistically significant correlation between the status of p53 in the primary lesion and the clinical features of recurrent HCCs examined, i.e., extrahepatic metastasis, the number of recurrent tumors, extent of recurrent tumors, and treatment for recurrent tumors. However, postrecurrence survival was significantly lower in patients in whom a p53 mutation had been detected in the primary lesion (P < 0.01). A multivariate analysis for prognostic value after recurrence revealed that the p53 mutation was a useful independent prognostic factor affecting survival after recurrence (P < 0.01). In conclusion, our findings suggest that HCCs with p53 mutations have a high malignant potential based on their poor prognosis. Therefore, a p53 mutation in the primary lesion is useful as an indicator of the biological behavior of recurrent HCCs.
引用
收藏
页码:849 / 855
页数:7
相关论文
共 30 条
[1]  
ACKERMAN NB, 1986, ARCH SURG-CHICAGO, V121, P726
[2]   CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].
BAKER, SJ ;
FEARON, ER ;
NIGRO, JM ;
HAMILTON, SR ;
PREISINGER, AC ;
JESSUP, JM ;
VANTUINEN, P ;
LEDBETTER, DH ;
BARKER, DF ;
NAKAMURA, Y ;
WHITE, R ;
VOGELSTEIN, B .
SCIENCE, 1989, 244 (4901) :217-221
[3]   PCR AMPLIFICATION OF UP TO 35-KB DNA WITH HIGH-FIDELITY AND HIGH-YIELD FROM LAMBDA-BACTERIOPHAGE TEMPLATES [J].
BARNES, WM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (06) :2216-2220
[4]   COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].
BERGH, J ;
NORBERG, T ;
SJOGREN, S ;
LINDGREN, A ;
HOLMBERG, L .
NATURE MEDICINE, 1995, 1 (10) :1029-1034
[5]   SELECTIVE G-MUTATION TO T-MUTATION OF P53 GENE IN HEPATOCELLULAR-CARCINOMA FROM SOUTHERN AFRICA [J].
BRESSAC, B ;
KEW, M ;
WANDS, J ;
OZTURK, M .
NATURE, 1991, 350 (6317) :429-431
[6]   PERCUTANEOUS ETHANOL INJECTION FOR THE TREATMENT OF SMALL HEPATOCELLULAR-CARCINOMA - STUDY OF 95 PATIENTS [J].
EBARA, M ;
OHTO, M ;
SUGIURA, N ;
KITA, K ;
YOSHIKAWA, M ;
OKUDA, K ;
KONDO, F ;
KONDO, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1990, 5 (06) :616-626
[7]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093
[8]  
Hayashi H, 1995, HEPATOLOGY, V22, P1702
[9]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[10]  
HSU HC, 1993, CANCER RES, V53, P4691